You are here: Industry Insights > siponimod

News List

NICE does not recommend Novartis’ siponimod for secondary progressive MS europeanpharmaceuticalreview
June 30, 2020
NICE has decided to not recommend Mayzent (siponimod) for use on the NHS as a secondary progressive multiple sclerosis treatment because its clinical trial did not directly compare it to interferon beta-1b.
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease worldpharmanews
March 28, 2019
Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis
Novartis Announces FDA, EMA Filing Acceptance of Siponimod americanpharmaceuticalreview
October 12, 2018
Novartis announced that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company's New Drug Application (NDA) and Marketing Authorization Application (MAA) respectively, for investigational oral, once-da
Novartis files MS drug siponimod in EU and US pharmatimes
October 11, 2018
Novartis is seeking approval on both sides of the Atlantic for use of experimental multiple sclerosis therapy siponimod to treat secondary progressive forms of the disease.
US, EU filings imminent for Novartis’ MS therapy siponimod pharmatimes
July 20, 2018
Novartis’ experimental multiple sclerosis therapy siponimod is on the brink of being filed in the US.